[Click eStock] "NKMax, Reconfirming the Potential for Super NK Growth"

KB Securities analyzed on the 1st that NKMAX's Super NK has confirmed growth potential. No investment opinion or target price was presented.

Clinical researcher Lim Sang-guk of KB Securities stated, "The final results of the US Phase 1 clinical trial related to refractory solid tumors (sarcoma) are expected to be announced within the year," adding, "Following the interim data, expectations are increasing for positive data from the final results, and the possibility of proceeding with global Phase 2 clinical trials and technology export is growing."

Researcher Lim also emphasized the need to pay attention to the Alzheimer's treatment using the autologous NK cell therapy SNK01. NKMAX's US subsidiary, NKGen Biotech, previously disclosed the final data of the Phase 1 Alzheimer's clinical trial conducted in Mexico at the US CTAD (Clinical Trials on Alzheimer's Disease) conference.

He explained, "During the clinical trial in Mexico, no treatment-related adverse effects were observed, and particularly in terms of efficacy, differentiated effects compared to existing drugs were observed, confirming both safety and efficacy."

Based on the successful Phase 1 clinical trial results in Mexico, NKMAX plans to conduct the first Alzheimer's Phase 1/2a clinical trial in the US among NK cell therapy companies. While up to 4 billion SNK01 cells were administered in the Mexico trial, the US trial plans to administer up to 6 billion cells to explore safety and efficacy regarding dosage.

Additionally, unlike the Mexico trial which included mild patients, the US trial will be conducted on 36 moderate patients, administering SNK01 a total of 17 times over 49 weeks.

Researcher Lim said, "SNK01 not only helps remove abnormal proteins such as amyloid-beta and tau targeted by existing antibody therapies but also reduces neuroinflammation, improving the immune environment in the brain, thereby increasing the development potential as an NK cell Alzheimer's treatment."

This content was produced with the assistance of AI translation services.